Breaking News

Drug targets women with defective BRCA genes found by new test
But MARIANNE trial finds Kadcyla treatment options non-inferior
Researchers find tobacco-specific nitrosamines
Risk reduced by 97% in subjects 50 years of age and older

Recent Headlines

CD3 T-cell engager joins ranks of world’s most expensive cancer treatments
NIH study examines prescribing patterns
Rate of functional independence nearly twice as high with clot removal versus usual care alone
Newest fluoroquinolone to win agency’s okay

FEATURED STORIES FROM P&T NOVEMBER 2014

Stephen Barlas

Over the past few years, safety and effectiveness have been the issues plaguing generic pharmaceuticals. But concern has largely faded about the quality of active pharmaceutical ingredients manufactured in places such as India or China, or the bioequivalence of products such as Budeprion XL 300 mg. Now a new series of question marks hovers over generic drugs.

Maria Sorbera PharmD
Elizabeth Chung PharmD
Christopher W. Ho PharmD, BCACP

INTRODUCTION

P&T TV

From Sovaldi to Ebola: A Wide-ranging Interview with Dr. David Nash

A leading authority on population health, Dr. David Nash is optimistic about the future of disruptive innovation to improve healthcare in the U.S. The interview was conducted by P&T Editor Sonja Sherritze.

Interview